Liver Diseases  >>  tasquinimod (ABR-215050)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
tasquinimod (ABR-215050) / Active Biotech, Ipsen
NCT01743469 / 2012-002326-75: A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers

Completed
2
201
Canada, Europe
Tasquinimod, ABR-215050
Ipsen
Advanced or Metastatic Hepatocellular Cancer, Advanced or Metastatic Ovarian Cancer, Metastatic Renal Cell Cancer, Advanced or Metastatic Gastric Carcinoma
12/14
04/16

Download Options